Victory for Catholic-Based Hospital Systems Across the 31-01-2023, 21:13

Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 27-10-2023, 23:15

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26